Author Correction: Complement as a target in COVID-19?

Affiliations

¹ Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
² National Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.
³ Institute of Experimental Trauma- Immunology, University Hospital of Ulm, Ulm, Germany.
⁴ Amyndas Pharmaceuticals, Glyfada, Greece.
⁵ Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
⁶ Humanitas University, Pieve Emanuele, Milan, Italy.
⁷ IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy. ciceri.fabio@hsr.it.
⁸ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. lambris@pennmedicine.upenn.edu.

Published Erratum

Antonio M Risitano et al. Nat Rev Immunol. 2020 Jul.

. 2020 Jul;20(7):448.

doi: 10.1038/s41577-020-0366-6.

¹ Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
² National Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.
³ Institute of Experimental Trauma- Immunology, University Hospital of Ulm, Ulm, Germany.
⁴ Amyndas Pharmaceuticals, Glyfada, Greece.
⁵ Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
⁶ Humanitas University, Pieve Emanuele, Milan, Italy.
⁷ IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy. ciceri.fabio@hsr.it.
⁸ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. lambris@pennmedicine.upenn.edu.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Complement as a target in COVID-19?
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Risitano AM, et al. Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23. Nat Rev Immunol. 2020. PMID: 32327719 Free PMC article.